Literature DB >> 8695353

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.

D Del Bufalo1, C Cucco, C Leonetti, G Citro, I D'Agnano, M Benassi, T Geiser, G Zon, B Calabretta, G Zupi.   

Abstract

We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the G1 phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695353      PMCID: PMC2074645          DOI: 10.1038/bjc.1996.370

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa.

Authors:  G Torelli; D Venturelli; A Coló; C Zanni; L Selleri; L Moretti; B Calabretta; U Torelli
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

3.  c-myb protein expression is a late event during T-lymphocyte activation.

Authors:  J S Lipsick; W J Boyle
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

Review 4.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

5.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

6.  Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells.

Authors:  B Drewinko; T L Loo; B Brown; J A Gottlieb; E J Freireich
Journal:  Cancer Biochem Biophys       Date:  1976-05

7.  Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus.

Authors:  B Majello; L C Kenyon; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma.

Authors:  K Alitalo; R Winqvist; C C Lin; A de la Chapelle; M Schwab; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.

Authors:  T L Burgess; E F Fisher; S L Ross; J V Bready; Y X Qian; L A Bayewitch; A M Cohen; C J Herrera; S S Hu; T B Kramer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin.

Authors:  M Grandi; C Geroni; F C Giuliani
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

View more
  3 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.

Authors:  Yanli Zhang; Chen Li; Xinfeng Liu; Yanlei Wang; Rui Zhao; Yongmei Yang; Xin Zheng; Yi Zhang; Xin Zhang
Journal:  EBioMedicine       Date:  2019-10-17       Impact factor: 8.143

3.  Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

Authors:  U Zangemeister-Wittke; T Schenker; G H Luedke; R A Stahel
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.